Japan’s MHLW Approves MPS VI Drug Naglazyme
This article was originally published in PharmAsia News
Executive Summary
Osaka-based AnGes MG announced that Naglazyme intravenousmucopolysaccharidosis VI drug was approved during the first session of Japan's Ministry of Health, Labor and Welfare Drug Review Board. MPS VI is a genetic disorder caused by the deficiency of arylsulfatase B, whereby the normal breakdown of dermatan sulfate and chondroitin sulfate is blocked and accumulates in the body. Naglazyme isa replacement therapy that infuses exogenous enzymes. It was designated an orphan drug by the MHLW in June 2008. AnGes MG signed a deal with manufacturer BioMarin Pharmaceutical and gained exclusive rights to market and distribute Naglazyme in Japan. (Click for more-Japanese language